A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
This study is testing a new personalized cancer vaccine combined with standard immunotherapy (BCG) to treat high-risk bladder cancer that hasn't spread into the bladder muscle. Researchers want to see if this combination works better than standard treatment alone at preventing the cancer from coming back or getting worse.
You may be eligible if you recently had surgery to remove high-risk bladder tumors that are still limited to the bladder lining. Participants must either be new to BCG treatment or have been cancer-free for at least two years since their last round of BCG.
Participants will be randomly assigned to receive either the standard BCG treatment or the combination of BCG and the new vaccine, V940. The vaccine is personalized, meaning it is created specifically for your own cells to help your immune system better identify and fight your cancer.
The study is currently recruiting patients at specific medical centers in California, including locations in Bakersfield, Los Alamitos, and Los Angeles. Please speak with your doctor to see if one of these centers is a good fit for your care.
- 1The study tests if adding a personalized vaccine to standard care improves cancer outcomes.
- 2Participation involves close monitoring by a research team to track your health and response to treatment.
- 3This trial is for patients whose cancer has not grown into the bladder muscle.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.